• About us
• Contact

Advertisement

Organisation › Details

Kymera Therapeutics Inc. (Nasdaq: KYMR)

Kymera Therapeutics is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Powered by Pegasus™, a game-changing integrated degradation platform, Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. *

 

	Start	2017-10-31 existent
	Industry	protein degradation drug
	Person	Mainolfi, Nello (Kymera Therapeutics 201911– CEO before CSO + Co-Founder before Raze Therapeutics)
	Person 2	Jacobs, Bruce (Kymera Therapeutics 201907– CFO before Westfield Capital Management + Alex Brown & Sons/Deutsche Bank)
	Street	200 Arsenal Yards Blvd. Suite 230
	City	02472 Watertown, MA
		Address record changed: 2024-01-05
Basic data	Employees	n. a.
		* Document for »About Section«: Vertex Pharmaceuticals Inc.. (5/15/19). "Press Release: Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases". Boston, MA & Cambridge, MA.
		Record changed: 2023-07-10

Advertisement

More documents for Kymera Therapeutics Inc. (Nasdaq: KYMR)

• [1] Kymera Therapeutics Inc.. (7/9/20). "Press Release: Kymera Therapeutics and Sanofi Enter into Strategic Partnership to Advance Novel Protein Degrader Therapies to Advance Novel Protein Degrader Therapies to Patients". Cambridge, MA....
• [2] Kintai Therapeutics, Inc.. (9/11/19). "Press Release: Kintai Therapeutics Appoints Senior Executive Dr. Mark E. Nuttall as Chief Business Officer". Cambridge, MA....
• [3] Kymera Therapeutics Inc.. (7/15/19). "Press Release: Kymera Therapeutics Announces Leadership Transitions. Nello Mainolfi Named President of the Company – Bruce Jacobs Appointed Chief Financial Officer". Cambridge, MA....
• [4] Kymera Therapeutics Inc.. (11/13/18). "Press Release: Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology". Cambridge, MA....
• [5] Kymera Therapeutics LLC. (4/4/18). "Press Release: Kymera Therapeutics Announces Discovery Collaboration with GSK to Advance New Treatment Modality". Cambridge, MA....
• [6] Kymera Therapeutics Inc.. (2/16/18). "Press Release: Kymera Therapeutics Appoints Industry Veteran Mark E. Nuttall, Ph.D., as Chief Business Officer. Don W. Nicholson, Ph.D. joins Board of Directors". Cambridge, MA....
• [7] Kymera Therapeutics LLC. (10/30/17). "Press Release: Kymera Therapeutics Announces Series A to Advance Novel Therapeutic Modality and Develop Innovative Therapies". Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.